Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: Assessment of infarct size with99mTc- annexin V

Journal of Nuclear Medicine

Volumn 49, Issue 10, 2008, Pages 1694-1700

  Doue, Tomoki ^a,b   Ohtsuki, Katsuichi ^a,b   Ogawa, Kazuma ^c   Ueda, Masashi ^d   Azuma, Akihiro ^a   Saji, Hideo ^e   Strauss, Harry W ^f   Matsubara, Hiroaki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MEIJI UNIVERSITY OF INTEGRATIVE MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

99mTc annexin V; Apoptosis; Erythropoietin; Reperfusion

Indexed keywords

ANNEXIN V TC 99M; ERYTHROPOIETIN; RADIOISOTOPE; SODIUM CHLORIDE; THALLIUM 201; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; CELL DENSITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ECHOCARDIOGRAPHY; FUNCTIONAL DISEASE; HEART; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HISTOLOGY; INJECTION; LEFT CORONARY ARTERY; MALE; NICK END LABELING; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; RISK; SINGLE DRUG DOSE;

ANIMALS; ANNEXIN A5; APOPTOSIS; AUTORADIOGRAPHY; CARDIOTONIC AGENTS; CORONARY VESSELS; ECHOCARDIOGRAPHY; ERYTHROPOIETIN; HEMATOCRIT; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; REPERFUSION INJURY; TECHNETIUM;

EID: 53749091719     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.050260     Document Type: Article

References (32)

1. Fliss H, Gautinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res. 1996;79:949-956.
2. Gottlieb RA, Burleson KO, Kloner RA, et al. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994;94:1621-1628.
3. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007.
4. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation. 2004;109:2050-2053.
5. Maulik N, Kagan VE, Tyurin VA, et al. Redistribution of phosphatidylethanolamine and phosphatidylserine precedes reperfusion-induced apoptosis. Am J Physiol. 1998;274:H242-H248.
6. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545-1556.
7. Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA. 1995;92:3717-3720.
8. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505.
9. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998;95:4635-4640.
10. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004;101:14907-14912.
11. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-4806.
12. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003;100:11612-11617.
13. Parsa CJ, Jihee K, Riel RU, et al. Cardioprotective effect of erythropoietin in the reperfused ischemic heart. J Biol Chem. 2004;279:20655-20662.
14. 99mTc-annexin V. J Nucl Med. 2004;45:1536-1541.
15. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipids asymmetry in blood cells. Blood. 1997;89:1121-1132.
16. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 1998;95:6349-6354.
17. 99mTc-labeled annexin V. J Nucl Med. 1999;40:184-191.
18. Fadok VA, Laszlo DJ, Noble PW, Weinstein L, Riches DW, Henson PM. Particle digestibility is required for induction of the phosphatidylserine recognition mechanism used by murine macrophages to phagocytose apoptotic cells. J Immunol. 1993;151:4274-4285.
19. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415-1420.
20. Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7:1347-1352.
21. 99mTc-labeled annexin V in experimental subacute myocarditis. J Nucl Med. 2004;45:1081-1086.
22. Bennink RJ, van den Hoff MJ, van Hemert FJ, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med. 2004;45:842-848.
23. 99mTc. Bioconjug Chem. 2000;11:918-925.
24. Dumont EA, Reutelingsperger CP, Smits JF, et al. Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med. 2001;7:1352-1355.
25. Dumont EA, Hofstra L, van Heerde WL, et al. Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. Circulation. 2000;102:1564-1568.
26. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 2000;356:209-212.
27. Cheung WK, Goon BL, Guilfoile MC, et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther. 1998;64:412-423.
28. Eder H, Rosslenbroich B, Failing K. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Blut. 1989;59:184-187.
29. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther. 2005;19: 33-40.
30. Roger SD, Baker LR, Raine AE. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO). Clin Nephrol. 1993;39:103-110.
31. Wolf RF, Gilmore LS, Friese P, Downs T, Burstein SA, Dale GL. Erythropoietin potentiates thrombus development in a canine arteriovenous shunt model. Thromb Haemost. 1997;77:1020-1024.
32. van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125-133.